Compare RNGR & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNGR | GLSI |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | 2300 | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.6M | 327.2M |
| IPO Year | 2017 | 2020 |
| Metric | RNGR | GLSI |
|---|---|---|
| Price | $15.92 | $23.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $20.00 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 173.9K | 132.6K |
| Earning Date | 04-27-2026 | 05-19-2026 |
| Dividend Yield | ★ 6.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.86 | N/A |
| Revenue Next Year | $4.37 | N/A |
| P/E Ratio | $132.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.14 | $7.78 |
| 52 Week High | $18.82 | $34.10 |
| Indicator | RNGR | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 47.94 | 46.15 |
| Support Level | $14.99 | $21.21 |
| Resistance Level | $16.89 | $29.89 |
| Average True Range (ATR) | 0.59 | 2.21 |
| MACD | 0.05 | -0.42 |
| Stochastic Oscillator | 54.55 | 29.93 |
Ranger Energy Services Inc offers high specification mobile rig well services, cased hole wireline services, and ancillary services in the U.S. oil and gas industry. Its services facilitate operations throughout the lifecycle of a well, including the completion, production, maintenance, intervention, workover, and abandonment phases. The company's reportable segments are: High Specification Rigs, Wireline Services, Processing Solutions and Ancillary Services. Maximum revenue is generated from the High Specification Rigs segment, which offers high specification well service rigs and complementary equipment and services to facilitate operations throughout the lifecycle of a well. The high specification rig services consist of well completion support, workovers, and well maintenance services.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.